Results 21 to 30 of about 86,566 (299)

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

HIV Medicine, 2022
To compare the incidence of hypertension in people living with HIV receiving integrase strand transfer inhibitor (INSTI)‐based antiretroviral therapy (ART) versus non‐nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted protease inhibitors ...
D. Byonanebye, M. Polizzotto, B. Neesgaard, M. Sarcletti, R. Matulionytė, D. Braun, A. Castagna, S. De Wit, F. Wit, E. Fontas, J. Vehreschild, J. Vesterbacka, L. Greenberg, C. Hatleberg, H. Garges, J. Gallant, A. Volny Anne, Angela Öllinger, I. Mozer‐Lisewska, Bernard Surial, V. Spagnuolo, C. Necsoi, M. van der Valk, A. Mocroft, M. Law, L. Ryom, K. Petoumenos   +26 more
semanticscholar   +1 more source

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]

PLoS ONE, 2012
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith, Dana N Raugi, Charlotte Pan, Matthew Coyne, Alexandra Hernandez, Brad Church, Kara Parker, James I Mullins, Papa Salif Sow, Geoffrey S Gottlieb, University of Washington-Dakar HIV-2 Study Group   +10 more
doaj   +1 more source

Recent Developments in the Synthesis of HIV-1 Integrase Strand Transfer Inhibitors Incorporating Pyridine Moiety

International Journal of Molecular Sciences, 2023
Human immunodeficiency virus (HIV) causes one of the most dangerous diseases—acquired immunodeficiency syndrome (AIDS). An estimated about 40 million people are currently living with HIV worldwide, most of whom are already on antiretroviral therapy. This
A. Starosotnikov, M. Bastrakov
semanticscholar   +1 more source

Small molecule inhibitors of the LEDGF site of human immunodeficiency virus integrase identified by fragment screening and structure based design. [PDF]

PLoS ONE, 2012
A fragment-based screen against human immunodeficiency virus type 1 (HIV) integrase led to a number of compounds that bound to the lens epithelium derived growth factor (LEDGF) binding site of the integrase catalytic core domain.
Thomas S Peat, David I Rhodes, Nick Vandegraaff, Giang Le, Jessica A Smith, Lisa J Clark, Eric D Jones, Jonathan A V Coates, Neeranat Thienthong, Janet Newman, Olan Dolezal, Roger Mulder, John H Ryan, G Paul Savage, Craig L Francis, John J Deadman   +15 more
doaj   +1 more source

Authentic HIV-1 Integrase Inhibitors [PDF]

Future Medicinal Chemistry, 2010
HIV-1 integrase (IN) is indispensable for HIV-1 replication and has become a validated target for developing anti-AIDS agents. In two decades of development of IN inhibition-based anti-HIV therapeutics, a significant number of compounds were identified as IN inhibitors, but only some of them showed antiviral activity.
Chenzhong, Liao, Christophe, Marchand, Terrence R, Burke, Yves, Pommier, Marc C, Nicklaus   +4 more
openaire   +2 more sources

Integrase Strand Transfer Inhibitors are Associated with Incident Diabetes Mellitus in People with HIV.

Clinical Infectious Diseases, 2022
BACKGROUND Integrase strand transfer inhibitors (INSTIs) are associated with weight gain in people with HIV (PWH). Less is known about the risk of other metabolic outcomes such as diabetes mellitus and hyperglycemia.
Jane A. O’Halloran, John M. Sahrmann, Luis Parra-Rodriguez, D. Vo, A. Butler, M. Olsen, W. Powderly   +6 more
semanticscholar   +1 more source

Prevalence of acquired resistance to HIV integrase strand transfer inhibitors (INSTIs) in clinical samples from treatment-experienced patients in Chile, 2012-2023. [PDF]

J Virus Erad
Ferrer P, Ramos V, Durán M, Maureira D, Beltrán C, Afani A.   +5 more
europepmc   +2 more sources

INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay

Viruses, 2021
Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral compounds that prevent the insertion of a DNA copy of the viral genome into the host genome by targeting the viral enzyme integrase (IN).
Steven J. Smith, Andrea Ferris, Xuezhi Zhao, Gary Pauly, Joel P. Schneider, Terrence R. Burke, Stephen H. Hughes   +6 more
doaj   +1 more source

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs

Viruses, 2021
Integrase strand transfer inhibitors (INSTIs) are currently recommended for the first line treatment of human immunodeficiency virus type one (HIV-1) infection. The first-generation INSTIs are effective but can select for resistant viruses.
Steven J. Smith, X. Zhao, D. Passos, D. Lyumkis, T. Burke, S. Hughes   +5 more
semanticscholar   +1 more source

Resistance to inhibitors of the human immunodeficiency virus type 1 integration

Brazilian Journal of Infectious Diseases, 2010
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
Daria J. Hazuda, PhD
doaj   +1 more source